Print This Post
This week Cognition Therapeutics reported encouraging topline results from their Phase 2 clinical trial of CT1812, an investigational drug being studied in people with dementia with Lewy bodies (DLB). An early phase trial funded by the National Institutes of Health (NIH), the SHIMMER study met its primary endpoints of demonstrating safety and tolerability. Further, improvements were seen in behavioral, functional, cognitive and movement measures.
One hundred thirty volunteers were randomly assigned to receive one of two doses of study drug or a placebo (with no active ingredients) for 6 months. Researchers measured changes in cognition (including cognitive fluctuations), everyday functioning, neuropsychiatric features, movement, and care partner distress. The study found that the drug was safe and well tolerated compared to placebo in, particularly in the lower strength (100 mg) of the study drug.
CT1812 slowed cognitive decline across three cognitive measures over placebo; fluctuations in attention declined by 91%. Treatment with CT1812 also slowed progression of neuropsychiatric features by 82%, with particularly strong results for anxiety, hallucinations, and delusions. Caregiver distress caused by these neuropsychiatric features improved during the study in the treatment group, but continued to worsen over time in the placebo group.
Further, Parkinsonian motor decline was slowed by 62% compared to placebo, and participants on the study drug experienced a 52% slowing of their decline in activities of daily living compared to placebo.
Additional data will be presented and discussed with the scientific community at the upcoming International Lewy Body Dementia Conference in January in Amsterdam. More information is available in a press release from Cognition Therapeutics
Alzheimer's Society
